Stockscreener 앱 받기
52.40
0.98%
0.51
시간 외 거래:
52.33
-0.07
-0.13%
전일 마감가:
$51.89
열려 있는:
$51.85
하루 거래량:
273.10K
Relative Volume:
0.52
시가총액:
$3.33B
수익:
-
순이익/손실:
$-145.21M
주가수익비율:
-22.78
EPS:
-2.3
순현금흐름:
$-140.12M
1주 성능:
-0.98%
1개월 성능:
+12.09%
6개월 성능:
+16.29%
1년 성능:
+13.79%
1일 변동 폭
$51.40
$52.50
1주일 범위
$51.08
$53.78
52주 변동 폭
$31.42
$58.26
문레이크 이뮤노테라퓨틱스 Stock (MLTX) Company Profile
명칭
Moonlake Immunotherapeutics
전화
41 41 510 8022
주소
DORFSTRASSE 29, ZUG
MLTX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
MLTX
Moonlake Immunotherapeutics
|
52.40 | 3.35B | 0 | -145.21M | -140.12M | -2.30 |
|
VRTX
Vertex Pharmaceuticals Inc
|
366.54 | 98.88B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.00 | 58.84B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
438.93 | 56.12B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
661.83 | 41.20B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
288.18 | 35.49B | 3.81B | -644.79M | -669.77M | -6.24 |
문레이크 이뮤노테라퓨틱스 Stock (MLTX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-07-28 | 개시 | Rothschild & Co Redburn | Neutral |
| 2025-05-19 | 업그레이드 | Wolfe Research | Peer Perform → Outperform |
| 2025-03-18 | 개시 | RBC Capital Mkts | Outperform |
| 2025-01-17 | 업그레이드 | Goldman | Neutral → Buy |
| 2024-11-05 | 재개 | Wedbush | Outperform |
| 2024-08-26 | 다운그레이드 | Wolfe Research | Outperform → Peer Perform |
| 2024-06-25 | 개시 | Oppenheimer | Outperform |
| 2024-04-02 | 개시 | Goldman | Neutral |
| 2024-02-15 | 개시 | Wolfe Research | Outperform |
| 2023-12-08 | 개시 | Citigroup | Buy |
| 2023-11-02 | 개시 | Stifel | Buy |
| 2023-09-14 | 다운그레이드 | Bryan Garnier | Buy → Neutral |
| 2023-08-31 | 개시 | Needham | Buy |
| 2023-06-15 | 개시 | Barclays | Equal Weight |
| 2023-05-01 | 개시 | Guggenheim | Buy |
| 2023-03-22 | 개시 | Wedbush | Outperform |
| 2023-03-09 | 개시 | BTIG Research | Buy |
| 2023-02-14 | 개시 | Cantor Fitzgerald | Overweight |
| 2023-02-02 | 개시 | Bryan Garnier | Buy |
| 2022-11-11 | 개시 | Jefferies | Buy |
| 2022-08-25 | 개시 | SVB Leerink | Outperform |
| 2022-07-21 | 개시 | H.C. Wainwright | Buy |
| 2022-07-07 | 개시 | Cowen | Outperform |
모두보기
문레이크 이뮤노테라퓨틱스 주식(MLTX)의 최신 뉴스
Rising Losses Might Change the Case for Investing in MoonLake Immunotherapeutics (MLTX) - simplywall.st
Intraday Charts Show Spike in MoonLake Immunotherapeutics ActivitySwing Trade Entry With Volume Triggers Released - beatles.ru
Goldman Sachs Boosts MoonLake Pharmaceuticals Target Price to $82, Maintains "Buy" Rating - AInvest
Clear Street Analyst Reiterates Buy Rating for MoonLake Immunotherapeutics with $108 Price Target - AInvest
MoonLake Bets Big On Its Nanobody Drug As Key Trials Approach - Finimize
MoonLake Immunotherapeutics Reports Q2 2025 Financials - TipRanks
Guggenheim reiterates Buy rating on Moonlake Immunotherapeutics stock By Investing.com - Investing.com South Africa
Guggenheim reiterates Buy rating on Moonlake Immunotherapeutics stock - Investing.com
MoonLake Immunotherapeutics reports Q2 EPS (87c), consensus (76c) - TipRanks
MoonLake Immunotherapeutics: Buy Rating Driven by Promising SLK Phase 3 Data and Strong Financial Position - TipRanks
Clear Street Initiates MoonLake Immunotherapeutics(MLTX.US) With Buy Rating, Announces Target Price $108 - 富途牛牛
MoonLake Immunotherapeutics reports results for the quarter ended June 30Earnings Summary - TradingView
MoonLake Immunotherapeutics reports second quarter 2025 financial results and provides a business update - MarketScreener
MoonLake Immunotherapeutics Q2 Loss Widens - MarketScreener
MoonLake Immunotherapeutics Reports Second Quarter 2025 Financial Results and Provides a Business Update - Ariva
Earnings Flash (MLTX) MoonLake Immunotherapeutics Posts Q2 Net Loss $0.87 a Share, vs. FactSet Est of $0.68 Loss - MarketScreener
MoonLake Immunotherapeutics SEC 10-Q Report - TradingView
MoonLake Immunotherapeutics Reveals September Timeline for Crucial Phase 3 Results, Secures $500M Financing - Stock Titan
How does MoonLake Immunotherapeutics compare to its industry peersDiscover stocks with explosive potential - Jammu Links News
Is it the right time to buy MoonLake Immunotherapeutics stockFree Consultation - Jammu Links News
What drives MoonLake Immunotherapeutics stock priceFree Stock Index Interpretation - Jammu Links News
How does MoonLake Immunotherapeutics generate profit in a changing economyDiscover top stock picks for aggressive growth - Jammu Links News
Is MoonLake Immunotherapeutics stock overvalued or undervaluedMaximize gains with professional stock picks - Jammu Links News
MoonLake Immunotherapeutics: Strategic Leadership Transition and Promising Clinical Progress Drive Buy Rating - TipRanks
Is MoonLake Immunotherapeutics a growth stock or a value stockTremendous wealth creation - Jammu Links News
What catalysts could drive MoonLake Immunotherapeutics stock higher in 2025Achieve remarkable returns with smart investing - Jammu Links News
What institutional investors are buying MoonLake Immunotherapeutics stockOutstanding capital returns - Jammu Links News
What are MoonLake Immunotherapeutics company’s key revenue driversIdentify breakout stocks before they peak - Jammu Links News
Published on: 2025-08-03 09:53:42 - Jammu Links News
What are analysts’ price targets for MoonLake Immunotherapeutics in the next 12 monthsPre Market Picks With High Returns - Jammu Links News
Phase 3 Trials Accelerate MoonLake Advances for Immunologic Disease Treatment - Insider Monkey
Pattern recognition hints at MoonLake Immunotherapeutics upsideReal-Time Analysis With Entry Targets In Progress - metal.it
MoonLake Immunotherapeutics Inches Toward Key Resistance — Will It BreakEntry Plan for Oversold Reversal Stocks Released - metal.it
Is Now a Good Time to Reenter MoonLake ImmunotherapeuticsSwing Trade Entry With Volume Triggers Released - metal.it
Published on: 2025-07-29 20:29:47 - beatles.ru
MoonLake Immunotherapeutics Company’s Quarterly Earnings Growth: What the Numbers SayWealth Building Stock Market Ideas Based on Momentum - metal.it
Promising Outlook for MoonLake Immunotherapeutics: Buy Rating Backed by Strong Position in Hidradenitis Suppurativa Treatment - TipRanks
What does MLTX's flat EPS in 2024 suggest for investors? - AInvest
Does MoonLake Immunotherapeutics stock perform well during market downturnsStock Market Data Feed For Consistent Profits - jammulinksnews.com
Published on: 2025-07-29 08:56:36 - metal.it
Published on: 2025-07-29 07:59:51 - metal.it
Published on: 2025-07-29 06:35:51 - metal.it
How strong is MoonLake Immunotherapeutics company’s balance sheetAchieve explosive financial results today - Jammu Links News
문레이크 이뮤노테라퓨틱스 (MLTX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.24%
3.39%
자본화:
|
볼륨(24시간):